Related Experiment Videos
Cardiac transplantation for Fabry's disease
W J Cantor1, P Daly, M Iwanochko
1Division of Cardiology, Toronto Hospital, Ontario.
The Canadian Journal of Cardiology
|March 6, 1998
Summary
Heart transplantation is a viable option for patients with end-stage Fabry cardiomyopathy. Early signs of Fabry disease recurrence in the allograft were not observed in long-term follow-up.
Area of Science:
- Cardiology
- Genetics
- Transplantation
Background:
- Fabry disease is a rare genetic disorder that can lead to severe cardiomyopathy.
- Cardiac transplantation for Fabry cardiomyopathy has not been previously reported.
- Disease recurrence in renal allografts is known, but cardiac allograft outcomes are unclear.
Observation:
- A 53-year-old female with end-stage Fabry cardiomyopathy underwent heart transplantation.
- Initial post-transplant biopsy showed Fabry inclusions, but these resolved over one year.
- No clinical evidence of Fabry cardiomyopathy recurrence was observed.
Findings:
- Heart transplantation is a potential treatment for end-stage Fabry cardiomyopathy.
- Early recurrence of Fabry disease in the cardiac allograft may not occur or may be transient.
- Absence of clinical symptoms suggests successful management post-transplantation.
Implications:
- Cardiac transplantation offers a viable therapeutic option for Fabry cardiomyopathy.
- Further long-term studies are necessary to confirm the safety and efficacy of heart transplantation for Fabry disease.
- Understanding allograft behavior in Fabry cardiomyopathy is crucial for patient management.